Wire · opportunities
Oncolytics Biotech Announces Progress in REO 033 Trial, Site Activations and FDA-Aligned ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 September 2026 · Fusion42 review
Oncolytics Biotech has activated nearly all planned clinical sites for its REO 033 trial evaluating pelareorep in metastatic colorectal cancer and expects interim data by year-end 2026. The company aligned with the FDA on a regulatory pathway that could allow accelerated approval based on objective response rate and full approval on progression-free survival.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 28 Sep 2026 and 29 Sep 2026.
◆ ◆ The Wire takeaway
You can prepare now to engage with clinical stakeholders as the FDA pathway opens a faster approval route for pelareorep in metastatic colorectal cancer. Accelerate patient enrolment efforts to capitalise on the pending interim data milestone at year-end.
◆ Coverage
2 sources · first reported 28 Sep 2026 · latest 29 Sep 2026
◆ Related on Wire
◆ Topics